Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome.
- Author:
Ji-min SHI
1
;
He HUANG
;
Zhen CAI
;
Yi LUO
;
Xiu-jin YE
;
Jie ZHANG
;
Li LI
;
Jing-song HE
;
Wan-zhuo XIE
;
Wei-yan ZHENG
;
Xiao-jian MENG
;
Mao-fang LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bone Marrow Transplantation; Busulfan; administration & dosage; Cyclophosphamide; administration & dosage; Female; Humans; Male; Myelodysplastic Syndromes; surgery; Transplantation Conditioning
- From: Journal of Zhejiang University. Medical sciences 2006;35(2):122-126
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation (BMT) with unrelated donor for myelodysplastic syndrome.
METHODSSix patients received chemotherapy regimen of busulfan (Bu) and cyclophosphamide (CY) before allogeneic BMT (Bu 4 mg . kg(-1) . d(-1), -7 d - -4 d, CY 60 mg . kg(-1) . d(-1), -3 d - -2 d). Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation. Lipo prostaglandin E(1)was used in prophylactic regimen for hepatic veno-occlusive disease.
RESULTNeutrophil count began to be higher than 0.5 x 10(9)/Lat the 18th day after BMT. Platelet count began to be higher than 20 x 10(9)/Lat the 21st day after BMT. Disease-free survival in the six patients was 27 months.
CONCLUSIONBu-CY(2) conditioning regimen on allogeneic bone marrow transplantation with unrelated donor is an effective therapy for patients with myelodysplastic syndrome.
